Key information

🔎 Fund Overview

Roivant Sciences Ltd. is a pharma company. The Company is focused on developing transformative medicines that address areas of unmet medical need. The Company, through its subsidiaries, is focused on delivering medicines and technologies to patients. The Company builds biotech and healthcare technology companies (Vants) and deploys technology to drive research and development and commercialization. The Company’s product candidate includes VTAMA (tapinarof), IMVT-1401, Brepocitinib, Namilumab and RVT-2001. Its Vant family includes Dermavant, Immunovant, Priovant, Kinevant and Hemavant. Its small molecule discovery engine is powered by computational physics and machine learning (ML) capabilities for in silico drug design. The Company’s capabilities in diverse therapeutic areas, including immunology, dermatology and oncology, and modalities, including biologics, topicals and bifunctional small molecules.